share_log

6-K: Financial Report for the Period 1 January 2024 to 30 September 2024

6-K: Financial Report for the Period 1 January 2024 to 30 September 2024

6-K：2024年1月1日至2024年9月30日期間的財務報告
美股SEC公告 ·  2024/11/06 03:37

Moomoo AI 已提取核心訊息

Novo Nordisk delivered robust financial results for the first nine months of 2024, with sales increasing 24% at CER to DKK 204.7 billion and operating profit growing 22% at CER to DKK 91.6 billion. The growth was primarily driven by GLP-1 diabetes sales rising 26% and Obesity care surging 44% to DKK 43.7 billion.The company achieved significant R&D milestones, including successful completion of the SOUL cardiovascular outcomes trial with oral semaglutide and positive ESSENCE trial results for semaglutide 2.4mg in MASH treatment. The phase 2a trial with monlunabant in obesity was completed, with plans to initiate a larger phase 2b trial in 2025.For 2024, Novo Nordisk has updated its outlook, now expecting sales growth of 23-27% at CER and operating profit growth of 21-27% at CER. The guidance reflects continued investments in supply chain expansion and R&D, while accounting for periodic supply constraints across products due to high demand. The company has increased its presence in obesity treatment markets and strengthened its diabetes care leadership with a 33.9% global value market share.
Novo Nordisk delivered robust financial results for the first nine months of 2024, with sales increasing 24% at CER to DKK 204.7 billion and operating profit growing 22% at CER to DKK 91.6 billion. The growth was primarily driven by GLP-1 diabetes sales rising 26% and Obesity care surging 44% to DKK 43.7 billion.The company achieved significant R&D milestones, including successful completion of the SOUL cardiovascular outcomes trial with oral semaglutide and positive ESSENCE trial results for semaglutide 2.4mg in MASH treatment. The phase 2a trial with monlunabant in obesity was completed, with plans to initiate a larger phase 2b trial in 2025.For 2024, Novo Nordisk has updated its outlook, now expecting sales growth of 23-27% at CER and operating profit growth of 21-27% at CER. The guidance reflects continued investments in supply chain expansion and R&D, while accounting for periodic supply constraints across products due to high demand. The company has increased its presence in obesity treatment markets and strengthened its diabetes care leadership with a 33.9% global value market share.
諾和諾德在2024年前九個月交出了強勁的財務業績，銷售額按不變貨幣增長24%，達到2047億丹麥克朗，營業利潤按不變貨幣增長22%，達到916億丹麥克朗。增長主要得益於GLP-1糖尿病藥物銷售增長26%和肥胖護理激增44%，達到437億丹麥克朗。公司取得了 знач大的研發里程碑，包括成功完成了口服賽美特利的SOUL心血管結果試驗和賽美特利2.4mg在MASH治療中的積極ESSENCE試驗結果。針對肥胖的monlunabant的2期試驗已經完成，計劃在2025年啓動一個更大規模的20億試驗。對於2024年，諾和諾德已更新其預期，現在預計銷量增長23%-27%（不變貨幣），營業利潤增長21%-27%（不變貨幣）。該指導反映了在供應鏈擴展和研發方面的持續投資，同時考慮到由於高需求各產品的週期性供應限制。公司在肥胖治療市場的存在得到了增強，並以33.9%的全球價值市場份額強化了其糖尿病護理領導地位。
諾和諾德在2024年前九個月交出了強勁的財務業績，銷售額按不變貨幣增長24%，達到2047億丹麥克朗，營業利潤按不變貨幣增長22%，達到916億丹麥克朗。增長主要得益於GLP-1糖尿病藥物銷售增長26%和肥胖護理激增44%，達到437億丹麥克朗。公司取得了 знач大的研發里程碑，包括成功完成了口服賽美特利的SOUL心血管結果試驗和賽美特利2.4mg在MASH治療中的積極ESSENCE試驗結果。針對肥胖的monlunabant的2期試驗已經完成，計劃在2025年啓動一個更大規模的20億試驗。對於2024年，諾和諾德已更新其預期，現在預計銷量增長23%-27%（不變貨幣），營業利潤增長21%-27%（不變貨幣）。該指導反映了在供應鏈擴展和研發方面的持續投資，同時考慮到由於高需求各產品的週期性供應限制。公司在肥胖治療市場的存在得到了增強，並以33.9%的全球價值市場份額強化了其糖尿病護理領導地位。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Medicus Pharma
    MDCX
    -- 3.310
    施貴寶
    BMY
    -- 60.815
    Scilex Holding
    SCLX
    -- 0.246
    強生
    JNJ
    -- 165.430
    安進
    AMGN
    -- 309.370
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日